Log In
BCIQ
Print this Print this
 

RE-001

  Manage Alerts
Collapse Summary General Information
Company Retrophin Inc.
DescriptionRecombinant fusion protein designed to substitute for dystrophin
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today